Cargando…
A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia
Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shenyang Pharmaceutical University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/ https://www.ncbi.nlm.nih.gov/pubmed/34849168 http://dx.doi.org/10.1016/j.ajps.2021.07.003 |
_version_ | 1784602927731572736 |
---|---|
author | Liu, Xiao Yin, Weiwei Widjaya, Andy Samuel Yang, Yueying Liu, Yunhu Jiang, Yanyan |
author_facet | Liu, Xiao Yin, Weiwei Widjaya, Andy Samuel Yang, Yueying Liu, Yunhu Jiang, Yanyan |
author_sort | Liu, Xiao |
collection | PubMed |
description | Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid syndrome, serious drug resistance and the short half-life in vivo which lead to frequent and large dose administration limit the application of ATRA. In addition, the preparations of arsenic are conventional injections and tablets in clinic, which has poor patients' compliance caused by frequent long-term administration and serious side effects. In order to overcome the above limitations, a phospholipid phase separation gel (PPSG) loaded with ATO and ATRA was developed. ATO+ATRA-PPSG (AAP), as a biodegradable sustained-release delivery system, was the first achievement of co-delivery of hydrophilic ATO and lipophilic ATRA with high drug loading which is the main problem in the application of nano preparation. The prepared PPSG displayed high safety and biocompatibility. The drug in PPSG was released slowly and continuously in vivo and in vitro for up to 10 d, which could reduce the side effects caused by the fluctuation of blood drug concentration and solve the problem of the long treatment cycle and frequent administration. In vivo pharmacokinetics depicted that PPSG could improve the bioavailability, decrease the peak concentration, and prolong the t(1/2) of ATO and ATRA. Particularly, AAP significantly inhibited the tumor volume, extended the survival period of tumor-bearing mice, and promoted the differentiation of APL cells into normal cells. Therefore, ATO+ATRA-PPSG not only could co-load hydrophilic ATO and lipophilic ATRA according to the clinical dosage, but also possessed the sustained-release and long-acting treatment effect which was expected to reduce administration time and ameliorate compliance of patients. Thus, it had great potential for clinical transformation and application. |
format | Online Article Text |
id | pubmed-8609443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Shenyang Pharmaceutical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-86094432021-11-29 A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia Liu, Xiao Yin, Weiwei Widjaya, Andy Samuel Yang, Yueying Liu, Yunhu Jiang, Yanyan Asian J Pharm Sci Original Research Paper Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid syndrome, serious drug resistance and the short half-life in vivo which lead to frequent and large dose administration limit the application of ATRA. In addition, the preparations of arsenic are conventional injections and tablets in clinic, which has poor patients' compliance caused by frequent long-term administration and serious side effects. In order to overcome the above limitations, a phospholipid phase separation gel (PPSG) loaded with ATO and ATRA was developed. ATO+ATRA-PPSG (AAP), as a biodegradable sustained-release delivery system, was the first achievement of co-delivery of hydrophilic ATO and lipophilic ATRA with high drug loading which is the main problem in the application of nano preparation. The prepared PPSG displayed high safety and biocompatibility. The drug in PPSG was released slowly and continuously in vivo and in vitro for up to 10 d, which could reduce the side effects caused by the fluctuation of blood drug concentration and solve the problem of the long treatment cycle and frequent administration. In vivo pharmacokinetics depicted that PPSG could improve the bioavailability, decrease the peak concentration, and prolong the t(1/2) of ATO and ATRA. Particularly, AAP significantly inhibited the tumor volume, extended the survival period of tumor-bearing mice, and promoted the differentiation of APL cells into normal cells. Therefore, ATO+ATRA-PPSG not only could co-load hydrophilic ATO and lipophilic ATRA according to the clinical dosage, but also possessed the sustained-release and long-acting treatment effect which was expected to reduce administration time and ameliorate compliance of patients. Thus, it had great potential for clinical transformation and application. Shenyang Pharmaceutical University 2021-09 2021-08-03 /pmc/articles/PMC8609443/ /pubmed/34849168 http://dx.doi.org/10.1016/j.ajps.2021.07.003 Text en © 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Paper Liu, Xiao Yin, Weiwei Widjaya, Andy Samuel Yang, Yueying Liu, Yunhu Jiang, Yanyan A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
title | A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
title_full | A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
title_fullStr | A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
title_full_unstemmed | A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
title_short | A practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
title_sort | practical strategy to subcutaneous administered in-situ gelling co-delivery system of arsenic and retinoic acid for the treatment of acute promyelocytic leukemia |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609443/ https://www.ncbi.nlm.nih.gov/pubmed/34849168 http://dx.doi.org/10.1016/j.ajps.2021.07.003 |
work_keys_str_mv | AT liuxiao apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT yinweiwei apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT widjayaandysamuel apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT yangyueying apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT liuyunhu apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT jiangyanyan apracticalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT liuxiao practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT yinweiwei practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT widjayaandysamuel practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT yangyueying practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT liuyunhu practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia AT jiangyanyan practicalstrategytosubcutaneousadministeredinsitugellingcodeliverysystemofarsenicandretinoicacidforthetreatmentofacutepromyelocyticleukemia |